genOway's capital increase will provide the company with additional resources for supporting its R&D policy which is aimed at improving its technology platform through proprietary innovation and license acquisitions, with a view to anticipating its clients’ future needs.
genOway has developed a sophisticated and robust industrialized technical platform aimed at providing the most suitable solutions to its clients' needs using well validated and fully secured technologies. Strategic alliances formed with leading companies such as Charles River Laboratories and Invitrogen Corporation, provide genOway’s customers with a comprehensive service including solutions upstream of model creation such as in vitro design and validation of shRNA and downstream services including cryopreservation of transgenic lines, accelerated backcrossing and phenotyping services.
Thanks to the all-encompassing range of services offered, genOway has reported a 67% sales increase in 2006 with a global yearly increase of 50% over the last 4 years. This rapid growth is supported by the company’s recent business results in North America and Japan. "Commercial agreements with major biopharmaceutical companies such as Bristol-Myers Squibb, Johnson & Johnson, Kyowa Hakko Kogyo, Ono Pharmaceuticals, etc. and leading research institutes such as Duke University Medical Center, National Institutes of Health, Universities of California in San Diego & San Francisco, University of Tokyo, etc. are encouraging and should reinforce our presence in these fast growing markets" said Alexandre Fraichard, the CEO of genOway.
